Cardiovascular Today—March 19, 2026

This week’s Cardiovascular update highlights clinical trial progress, product launches, real-world evidence growth, regenerative approvals, and advances in stroke prevention and care delivery.

In Today’s Newsletter

Dive deeper

🧠 Route 92 Medical starts SUMMIT RISE stroke study [1] [US • 09 Mar 2026]

https://neuronewsinternational.com/route-92-begins-enrolment-in-summit-rise-study-evaluating-companys-stroke-reperfusion-technologies/
Context: Route 92 Medical began a prospective, multicentre, open-label, core lab-adjudicated post-clearance study in acute ischaemic stroke, targeting 500 patients across 50 sites.
Key point: The first patient was enrolled in SUMMIT RISE, which will assess real-world performance of the company’s reperfusion systems across varied stroke scenarios and vessel sizes.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

❤️ CathWorks FFRangio adoption rises in US Medicare data [2] [US • 09 Mar 2026]

https://cardiovascularnews.com/crt-2026-late-breaking-data-highlight-growing-adoption-of-angiography-derived-fractional-flow-reserve/
Context: Investigators presented US Medicare outcomes at CRT 2026 and reported matched comparisons in PCI and non-PCI cohorts through two years.
Key point: Angiography-derived physiology use grew nearly eightfold from 2019 to 2024, and CathWorks said outcomes were similar to invasive pressure wire-guided strategies through two years.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 POLY-ACS tests a post-ACS polypill strategy [3] [US • 10 Mar 2026]

https://www.prnewswire.com/news-releases/ajpc-publishes-poly-acs-trial-demonstrating-feasibility-of-polypill-strategy-after-acute-coronary-syndrome-302709834.html
Context: The randomized trial enrolled 140 patients with recent acute coronary syndrome at two Dallas hospitals, with 30-day follow-up.
Key point: POLY-ACS reported that a polypill including aspirin, a high-intensity statin, and a P2Y12 inhibitor was feasible and maintained short-term lipid control and platelet inhibition versus usual care.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Johnson & Johnson expands its aspiration-first stroke portfolio [4] [US • 11 Mar 2026]

https://www.todaysmedicaldevelopments.com/news/johnson-johnson-launches-two-new-aspiration-catheters-ischemic-stroke-treatment/
Context: Johnson & Johnson launched CEREGLIDE 42, CEREGLIDE 57, and the INNERGLIDE 7 delivery aid in the US for ischemic stroke procedures.
Key point: The company said the additions complete the CEREGLIDE portfolio and are intended to improve distal clot access, procedural consistency, and compatibility across stroke cases.
Implication: Signals pipeline investment and modality expansion.

🩺 Verve Medical treats first patient in renal pelvic denervation pilot [5] [US • 12 Mar 2026]

https://cardiovascularnews.com/first-patient-treated-in-us-trial-of-renal-pelvic-denervation-technology/
Context: The randomized, double-blinded US pilot is enrolling 60 patients at 10 sites, with sham control for uncontrolled hypertension.
Key point: Verve Medical treated the first patient in its renal pelvic denervation trial, advancing a urology-based radiofrequency approach that targets renal nerves via the urinary tract.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ Emboline raises capital ahead of Emboliner launch [6] [US/EU • 12 Mar 2026]

https://cardiovascularnews.com/emboline-secures-funding-to-support-launch-of-embolic-protection-system/
Context: Emboline completed enrollment in the PROTECT H2H IDE trial and said late-breaking trial results will be presented at ACC 2026.
Key point: The company closed US$20 million in growth financing to support commercial launch activities and continued development of its embolic protection platform.
Implication: Signals pipeline investment and modality expansion.

🧬 Japan conditionally approves two stem cell therapies [7] [Japan • 14 Mar 2026]

https://www.medicalnewstoday.com/articles/japan-first-approve-stem-cell-treatments-parkinsons-heart-failure
Context: Japan granted conditional approval to Sumitomo Pharma’s AMCHEPRY for Parkinson’s disease and Cuorips’ RiHEART for severe heart failure.
Key point: The approvals mark a first for iPSC-based regenerative therapies in these indications, but the cited evidence base was small and non-randomized.
Implication: May influence prescriber choice and payer reviews pending full data.

🚑 Pre-MIRACLE2 moves neurological risk scoring into the field [8] [UK/US • 14 Mar 2026]

https://medicalxpress.com/news/2026-03-algorithm-paramedics-brain-cardiac.html
Context: RAPID-MIRACLE evaluated use of the MIRACLE2 score after return of spontaneous circulation in out-of-hospital cardiac arrest, with findings presented at CRT 2026 and published in European Heart Journal: Acute Cardiovascular Care.
Key point: Investigators reported that a pre-hospital version without a blood test, Pre-MIRACLE2, retained near-equivalent accuracy while being more practical for paramedics.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧠 OCEANIC-STROKE reports secondary prevention benefit with asundexian [9] [17 Mar 2026]

https://www.neurologylive.com/view/results-of-oceanic-stroke-trial-for-secondary-stroke-prevention
Context: Experts discussing results presented at ISC 2026 described outcomes in patients treated after ischemic stroke or TIA on background antiplatelet therapy.
Key point: The source reports that asundexian reduced first ischemic stroke and other vascular outcomes versus placebo, without an increase in major or intracranial bleeding.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Stroke intervention remains a major product and evidence focus, with Route 92, Johnson & Johnson, and OCEANIC-STROKE all pointing to device or drug efforts to improve outcomes after acute cerebrovascular events [1][4][9].
Cardiovascular care is moving on both workflow and regimen simplification, with FFRangio adoption data and POLY-ACS both framed around practical implementation in routine care [2][3].
Hypertension and structural heart interventions continue to attract medtech capital and trial activity, shown by Verve’s first-patient milestone and Emboline’s financing ahead of launch planning [5][6].
Japan’s conditional approvals show how regenerative medicine may reach patients earlier under time-limited frameworks, though evidence depth remains a central question [7].
Pre-hospital decision support is becoming more operational, with Pre-MIRACLE2 aiming to guide triage before hospital arrival rather than after admission [8].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What is SUMMIT RISE studying in Route 92 Medical’s program?

SUMMIT RISE is a 500-patient, post-clearance, real-world study of Route 92 Medical’s stroke reperfusion systems across different vessel sizes, sites, and clinician settings. The source describes prospective data collection with independent adjudication. [1]

What did the CathWorks FFRangio update actually show?

The report says angiography-derived physiology use increased sharply in US Medicare data and that matched outcomes were similar to invasive pressure wire-guided strategies through two years. It is an observational comparison, not a new randomized trial. [2]

Why is POLY-ACS notable after acute coronary syndrome?

POLY-ACS is described as the first randomized trial to use a polypill that includes a P2Y12 agent after ACS. The source says it showed short-term feasibility over 30 days, not definitive long-term outcome benefit. [3]

What is different about Verve Medical’s renal pelvic denervation approach?

Verve’s system targets renal nerves through the urinary tract rather than from inside the renal arteries. The current US pilot is randomized and sham-controlled, but it is still early-stage clinical testing. [5]

Why are Japan’s stem cell approvals important, and why the caution?

Japan conditionally approved AMCHEPRY for Parkinson’s disease and RiHEART for severe heart failure, which the source describes as world-first approvals in these settings. The same source notes the underlying studies were very small and lacked randomized control groups. [7]

What stands out from OCEANIC-STROKE?

The cited discussion reports reduced recurrent ischemic stroke and other vascular outcomes with asundexian on top of antiplatelet therapy, with no increase in major bleeding. The newsletter entry stays source-faithful to the discussion format provided. [9]

Entities / Keywords

Route 92 Medical, SUMMIT RISE, HiPoint 88, stroke reperfusion, acute ischaemic stroke
CathWorks, FFRangio, angiography-derived physiology, angiography-derived fractional flow reserve, ADP, PCI
POLY-ACS, polypill, acute coronary syndrome, ACS, P2Y12 inhibitor, AJPC
Johnson & Johnson MedTech, CEREGLIDE 42, CEREGLIDE 57, INNERGLIDE 7, aspiration catheter, thrombectomy
Verve Medical, renal pelvic denervation, RPD, TUSK trial, uncontrolled hypertension
Emboline, Emboliner, embolic protection system, PROTECT H2H, structural heart
Sumitomo Pharma, AMCHEPRY, induced pluripotent stem cells, iPSC, Parkinson’s disease
Cuorips, RiHEART, heart failure, regenerative medicine, stem cell-derived cardiomyocytes
MIRACLE2, Pre-MIRACLE2, RAPID-MIRACLE, out-of-hospital cardiac arrest, OHCA, paramedic triage
Asundexian, OCEANIC-STROKE, secondary stroke prevention, factor XI inhibition, ischemic stroke, TIA